According to a recent article in Biospace ,"The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, ...

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - November 12 ... have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or ...

Investorideas.com, a go-to investing platform, releases an industry snapshot looking at the future of medical technology ...

As the primary caregiver to his mother and partner, he was familiar with NewYork-Presbyterian/Columbia in Washington Heights and ... received a treatment call pembrolizumab (brand name: Keytruda) ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...

Among patients with early triple-negative breast cancer, treatment with Keytruda (pembrolizumab) demonstrated real-world evidence of immune-related adverse effects (irAEs) comparable with KEYNOTE-522, ...

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless of ...

An outspoken Columbia University professor, who has accused the school of being a hotbed of antisemitism, has been temporarily banned from its campus. Columbia said it isn’t letting Shai Davidai ...

By Vimal Patel and Sharon Otterman Columbia University has temporarily barred a vocal pro-Israel professor from campus, saying he repeatedly harassed and intimidated the school’s employees.

Merck's diversified pipeline includes promising oncology candidates and a new pneumococcal vaccine, but lacks a ready-made Keytruda replacement. Investors should monitor R&D updates closely ...

Prostate cancer has proved an elusive target for cancer immunotherapies, and Merck & Co's checkpoint inhibitor Keytruda is the latest to fall short in the disease in a phase 3 trial. Merck has ...